Program Overview
New, actionable data on the use of sodium-glucose co-transporter-2 (SGLT2) inhibitors was released at several major meetings in 2022, culminating in November at ASN/Kidney Week that herald signal advances in the management of DKD/T2D. These new data and an expert contextualization of their role in contemporary practice is the basis of this webcast.
Target Audience
Nephrologists, diabetologists, other internists, primary care providers, PAs, nurses and NPs, pharmacists, and other healthcare professionals who are involved in the management of patients with T2D and CKD in North America and in Europe.
Agenda
I. Review and analyze the latest therapeutic advances for the management of DKD in the setting of T2D as presented and explored at major congresses in 2022, with an emphasis on SGLT-2 inhibitor therapy
II. Apply new data and therapeutic advances into evidence-driven treatment strategies to improve the care of patients T2D and DKD
Learning Objectives
- Review and analyze the latest therapeutic advances for the management of DKD in the setting of T2D as presented and explored at major congresses in 2022, with an emphasis on SGLT-2 inhibitor therapy
- Apply new data and therapeutic advances into evidence-driven treatment strategies to improve the care of patients T2D and DKD
Faculty
Sophia Ambruso, MD
Clinical Nephrologist
Assistant Professor
Rocky Mountain VA Medical Center
University of Colorado School of Medicine
Aurora, Colorado
Will Herrington, MA, MBBS, MD
Clinician Scientist
Nuffield Department of Population Health
University of Oxford
Oxfordshire, England
Parminder Judge, MD
Senior Clinical Research Fellow
Nuffield Department of Population Health
University of Oxford
Oxfordshire, England
Disclosures of Relevant Financial Relationships
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.
Planners and faculty have no relevant financial relationships with ineligible companies for this activity, with the exception of the following:
| Faculty | Relationship Identified With: |
| Sophia Ambruso, MD | Consultant/Advisor: AstraZeneca |
| Will Herrington, MA, MBBS, MD | Research/Grant Support: Boehringer Ingelheim; Lilly; Medical Research UK; Kidney Research UK |
| Parminder Judge, MD | Research/Grant Support: Boehringer Ingelheim; Lilly; Medical Research UK; Kidney Research UK |
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC, Nicole McMenamin and Chelsey Simonds hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this live material for a maximum of 1.25 AMA PRA Category 1 CreditsTM.
Clinicians should claim only the credit commensurate with the extent of their participation in the activity.
Financial Support
This activity has been supported by an independent educational grant from the Boehringer Ingelheim/Lilly Alliance.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and the Boehringer Ingelheim/Lilly Alliance do not recommend the use of any agent outside of the labeled indications.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 50% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].
